Research progress of immune checkpoint inhibitors in ovarian cancer
Ovarian cancer is the deadliest malignant tumor in the female reproductive system. Despite advancements in standard treatments such as tumor debulking surgery and platinum-based chemotherapy, the overall survival rate remains low. The emergence of targeted therapies, including Poly(ADP-ribose) polym...
Saved in:
| Main Authors: | Lingli Zhao, Yanhong Zhai, Gaoli Niu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration Publishing Inc.
2024-12-01
|
| Series: | Exploration of Immunology |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/Journals/ei/Article/1003177 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Research progress of immune checkpoint inhibitors in the treatment of glioblastoma
by: JIA Xiaorong, et al.
Published: (2024-05-01) -
Effects of combined radiotherapy with immune checkpoint blockade on immunological memory in luminal-like subtype murine bladder cancer model
by: JiaMin Huang, et al.
Published: (2024-12-01) -
The growing potential of tofacitinib in immune checkpoint inhibitor-induced colitis: identifying remaining puzzle pieces
by: Raffaele Pellegrino, et al.
Published: (2024-11-01) -
Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer
by: A.E. Connor, et al.
Published: (2024-10-01) -
Progress in immunotherapy for brain metastatic melanoma
by: Shicheng Zheng, et al.
Published: (2025-01-01)